Cargando…
SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant
One of the features distinguishing SARS-CoV-2 from its more pathogenic counterpart SARS-CoV is the presence of premature stop codons in its ORF3b gene. Here, we show that SARS-CoV-2 ORF3b is a potent interferon antagonist, suppressing the induction of type I interferon more efficiently than its SARS...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473339/ https://www.ncbi.nlm.nih.gov/pubmed/32941788 http://dx.doi.org/10.1016/j.celrep.2020.108185 |
_version_ | 1783579165734207488 |
---|---|
author | Konno, Yoriyuki Kimura, Izumi Uriu, Keiya Fukushi, Masaya Irie, Takashi Koyanagi, Yoshio Sauter, Daniel Gifford, Robert J. Nakagawa, So Sato, Kei |
author_facet | Konno, Yoriyuki Kimura, Izumi Uriu, Keiya Fukushi, Masaya Irie, Takashi Koyanagi, Yoshio Sauter, Daniel Gifford, Robert J. Nakagawa, So Sato, Kei |
author_sort | Konno, Yoriyuki |
collection | PubMed |
description | One of the features distinguishing SARS-CoV-2 from its more pathogenic counterpart SARS-CoV is the presence of premature stop codons in its ORF3b gene. Here, we show that SARS-CoV-2 ORF3b is a potent interferon antagonist, suppressing the induction of type I interferon more efficiently than its SARS-CoV ortholog. Phylogenetic analyses and functional assays reveal that SARS-CoV-2-related viruses from bats and pangolins also encode truncated ORF3b gene products with strong anti-interferon activity. Furthermore, analyses of approximately 17,000 SARS-CoV-2 sequences identify a natural variant in which a longer ORF3b reading frame was reconstituted. This variant was isolated from two patients with severe disease and further increased the ability of ORF3b to suppress interferon induction. Thus, our findings not only help to explain the poor interferon response in COVID-19 patients but also describe the emergence of natural SARS-CoV-2 quasispecies with an extended ORF3b gene that may potentially affect COVID-19 pathogenesis. |
format | Online Article Text |
id | pubmed-7473339 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | The Authors. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74733392020-09-08 SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant Konno, Yoriyuki Kimura, Izumi Uriu, Keiya Fukushi, Masaya Irie, Takashi Koyanagi, Yoshio Sauter, Daniel Gifford, Robert J. Nakagawa, So Sato, Kei Cell Rep Report One of the features distinguishing SARS-CoV-2 from its more pathogenic counterpart SARS-CoV is the presence of premature stop codons in its ORF3b gene. Here, we show that SARS-CoV-2 ORF3b is a potent interferon antagonist, suppressing the induction of type I interferon more efficiently than its SARS-CoV ortholog. Phylogenetic analyses and functional assays reveal that SARS-CoV-2-related viruses from bats and pangolins also encode truncated ORF3b gene products with strong anti-interferon activity. Furthermore, analyses of approximately 17,000 SARS-CoV-2 sequences identify a natural variant in which a longer ORF3b reading frame was reconstituted. This variant was isolated from two patients with severe disease and further increased the ability of ORF3b to suppress interferon induction. Thus, our findings not only help to explain the poor interferon response in COVID-19 patients but also describe the emergence of natural SARS-CoV-2 quasispecies with an extended ORF3b gene that may potentially affect COVID-19 pathogenesis. The Authors. 2020-09-22 2020-09-04 /pmc/articles/PMC7473339/ /pubmed/32941788 http://dx.doi.org/10.1016/j.celrep.2020.108185 Text en © 2020 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Report Konno, Yoriyuki Kimura, Izumi Uriu, Keiya Fukushi, Masaya Irie, Takashi Koyanagi, Yoshio Sauter, Daniel Gifford, Robert J. Nakagawa, So Sato, Kei SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant |
title | SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant |
title_full | SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant |
title_fullStr | SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant |
title_full_unstemmed | SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant |
title_short | SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant |
title_sort | sars-cov-2 orf3b is a potent interferon antagonist whose activity is increased by a naturally occurring elongation variant |
topic | Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473339/ https://www.ncbi.nlm.nih.gov/pubmed/32941788 http://dx.doi.org/10.1016/j.celrep.2020.108185 |
work_keys_str_mv | AT konnoyoriyuki sarscov2orf3bisapotentinterferonantagonistwhoseactivityisincreasedbyanaturallyoccurringelongationvariant AT kimuraizumi sarscov2orf3bisapotentinterferonantagonistwhoseactivityisincreasedbyanaturallyoccurringelongationvariant AT uriukeiya sarscov2orf3bisapotentinterferonantagonistwhoseactivityisincreasedbyanaturallyoccurringelongationvariant AT fukushimasaya sarscov2orf3bisapotentinterferonantagonistwhoseactivityisincreasedbyanaturallyoccurringelongationvariant AT irietakashi sarscov2orf3bisapotentinterferonantagonistwhoseactivityisincreasedbyanaturallyoccurringelongationvariant AT koyanagiyoshio sarscov2orf3bisapotentinterferonantagonistwhoseactivityisincreasedbyanaturallyoccurringelongationvariant AT sauterdaniel sarscov2orf3bisapotentinterferonantagonistwhoseactivityisincreasedbyanaturallyoccurringelongationvariant AT giffordrobertj sarscov2orf3bisapotentinterferonantagonistwhoseactivityisincreasedbyanaturallyoccurringelongationvariant AT sarscov2orf3bisapotentinterferonantagonistwhoseactivityisincreasedbyanaturallyoccurringelongationvariant AT nakagawaso sarscov2orf3bisapotentinterferonantagonistwhoseactivityisincreasedbyanaturallyoccurringelongationvariant AT satokei sarscov2orf3bisapotentinterferonantagonistwhoseactivityisincreasedbyanaturallyoccurringelongationvariant |